Jazz Pharmaceuticals Public (NAS: JAZZ) is expected to report Q1 earnings on May 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will increase 75.7% and EPS will expand 48.4%.
The average estimate for revenue is $190.5 million. On the bottom line, the average EPS estimate is $1.35.
Last quarter, Jazz Pharmaceuticals Public tallied revenue of $181.9 million. GAAP reported sales were much higher than the prior-year quarter's $83.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.53. GAAP EPS of $3.27 for Q4 were 314% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 87.2%, 820 basis points worse than the prior-year quarter. Operating margin was 38.0%, much worse than the prior-year quarter. Net margin was 109.2%, much better than the prior-year quarter.
The full year's average estimate for revenue is $825.5 million. The average EPS estimate is $5.82.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 227 members out of 290 rating the stock outperform, and 63 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give Jazz Pharmaceuticals Public a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $66.91.
Add Jazz Pharmaceuticals Public to My Watchlist.
The article What to Expect from Jazz Pharmaceuticals Public originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.